The total return over the past 12 months is -97.68% vs. +16.94% for the S&P 500. So far it's up -96.57% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (97.68%) | (75.01%) | (69.81%) | (54.76%) | N/A | N/A |
| Total Return CAGR | (97.68%) | (75.01%) | (69.81%) | (54.76%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Enlivex Therapeutics Ltd. (ENLV)
| Year | Start price | End price | ENLV Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $10.55 | $0.36 | (96.57%) | +14.51% | (111.08%) |
| 2025 | $17.55 | $10.55 | (39.89%) | +17.72% | (57.61%) |
| 2024 | $40.50 | $17.55 | (56.67%) | +24.89% | (81.56%) |
| 2023 | $59.10 | $40.50 | (31.47%) | +26.19% | (57.66%) |
| 2022 | $93.75 | $59.10 | (36.96%) | (18.17%) | (18.79%) |
| 2021 | $126.45 | $93.75 | (25.86%) | +28.74% | (54.60%) |
| 2020 | $125.85 | $126.45 | +0.48% | +18.37% | (17.89%) |
| 2019 | $92.85 | $125.85 | +35.54% | +31.22% | +4.32% |
| 2018 | $274.35 | $92.85 | (66.16%) | (4.56%) | (61.60%) |
| 2017 | $624.00 | $274.35 | (56.03%) | +21.70% | (77.73%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
